Kyverna Therapeutics, Inc. (KYTX)
KYTX moved a median of -0.52% 30 minutes after news, and -1.50% by the close. How KYTX actually reacts to news — the realized, point-in-time move the market made, measured across 1,026 labeled events over the last three years with zero look-ahead.
KYTX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.07% | 41% | 1,005 |
| 30-min | -0.52% | 40% | 1,024 |
| 60-min | -0.44% | 39% | 1,024 |
| to close | -1.50% | 31% | 1,021 |
| Middle 50% of KYTX reactions | -1.50% to +1.00% |
|---|---|
| Median reaction (30-min) | -0.52% |
| Measured reactions | 1,026 |
Half of all Kyverna Therapeutics, Inc. news events land between -1.50% and +1.00% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How KYTX reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 21 | -1.71% | 24% | -1.95% |
| Rating reiterations | 31 | +0.13% | 58% | -0.38% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 4 further classes were observed with fewer than 10 measured events and are not published. See how KYTX ranks against every other measured name →
That’s how KYTX usually reacts — get an email when it moves on news →Email me when KYTX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to KYTX's baseline. Nothing else.
Recent KYTX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Kyverna Therapeutics to Present Positive Data in Stiff Person Syndrome and Progressive Multiple Sclerosis at MSToronto2026 | Press release | GlobeNewswire | -0.37% | +0.82% | |
| Form 8-K Kyverna Therapeutics, For: Sep 24 | SEC filing · Form 8-K | SEC EDGAR | +0.13% | -10.38% | |
| Kyverna Therapeutics Reports Positive One-Year Data Demonstrating Durable Clinical Responses and Favorable Safety Profile for Miv-cel in Stiff Person Syndrome and Generalized Myasthenia Gravis | Press release | GlobeNewswire | +0.13% | -10.38% | |
| Kyverna Therapeutics to Present at Upcoming Investor Conferences | Press release | GlobeNewswire | -0.10% | -4.13% | |
| Form 10-Q Kyverna Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.51% | +1.64% | |
| Form 8-K Kyverna Therapeutics, For: Aug 11 | SEC filing · Form 8-K | SEC EDGAR | +0.51% | +1.64% | |
| Kyverna Therapeutics Reports Pipeline Progress and Second Quarter 2026 Financial Results | Press release | GlobeNewswire | +0.51% | +1.64% | |
| Form 8-K Kyverna Therapeutics, For: Jul 23 | SEC filing · Form 8-K | SEC EDGAR | +3.28% | +6.17% | |
| Kyverna Therapeutics and ElevateBio Enter into Commercial Manufacturing and Supply Agreement for Miv-cel | Press release | GlobeNewswire | +3.28% | +6.17% | |
| Form 8-K Kyverna Therapeutics, For: Jul 08 | SEC filing · Form 8-K | SEC EDGAR | -0.30% | -1.70% | |
| Kyverna Therapeutics Appoints Ritesh Srivastava as Chief Legal and Compliance Officer, Adding Leadership Strength to Support Commercial-Stage Transition | Press release | GlobeNewswire | +1.93% | +0.00% | |
| Kyverna Therapeutics Highlights Updated Miv-cel Data at EULAR Demonstrating Substantial Reduction in Disease Activity in ACPA-Positive, Treatment Refractory Rheumatoid Arthritis | Press release | GlobeNewswire | +0.77% | -0.26% | |
| Form 8-K Kyverna Therapeutics, For: May 27 | SEC filing · Form 8-K | SEC EDGAR | +0.77% | -0.26% | |
| Form 8-K Kyverna Therapeutics, For: May 14 | SEC filing · Form 8-K | SEC EDGAR | -1.28% | -8.56% | |
| Kyverna Therapeutics Names Greg Martini as Chief Financial Officer | Press release | GlobeNewswire | -1.28% | -8.56% | |
| Kyverna Therapeutics to Present at Upcoming Investor Conferences | Press release | GlobeNewswire | +1.49% | +0.19% | |
| Form 10-Q Kyverna Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +5.13% | +4.76% | |
| Form 8-K Kyverna Therapeutics, For: May 12 | SEC filing · Form 8-K | SEC EDGAR | +5.13% | +4.76% | |
| Kyverna Therapeutics Announces Initiation of Rolling SPS BLA Submission and Reports First Quarter 2026 Financial Results | Press release | GlobeNewswire | +5.13% | +4.76% | |
| Form 8-K Kyverna Therapeutics, For: May 04 | SEC filing · Form 8-K | SEC EDGAR | +1.59% | +2.16% | |
| Kyverna Therapeutics Appoints Nadia Dac, Seasoned Commercial Leader in Neurology and Rare Disease, as Chief Commercial Officer | Press release | GlobeNewswire | +1.59% | +2.16% | |
| Form 8-K Kyverna Therapeutics, For: Apr 21 | SEC filing · Form 8-K | SEC EDGAR | -11.73% | -7.67% | |
| Form 8-K Kyverna Therapeutics, For: Apr 22 | SEC filing · Form 8-K | SEC EDGAR | -11.73% | -7.67% | |
| Kyverna Presents Registrational Trial Primary Analysis for Miv-cel in Stiff Person Syndrome Demonstrating Statistically Significant, Durable Clinical Benefit Across All Endpoints in an Oral, Late-Breaker Session at AAN Annual Meeting | Press release | GlobeNewswire | -11.73% | -7.67% | |
| Form 8-K Kyverna Therapeutics, For: Apr 20 | SEC filing · Form 8-K | SEC EDGAR | +2.05% | +9.76% | |
| Kyverna Presents Longer-Term Phase 2 Data for Miv-cel in Generalized Myasthenia Gravis at AAN, Demonstrating Deep, Durable Responses through 52 Weeks | Press release | GlobeNewswire | +2.05% | +9.76% | |
| Form ARS Kyverna Therapeutics, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -0.57% | -2.60% | |
| Form DEF 14A Kyverna Therapeutics, For: May 27 | SEC filing · Form DEF | SEC EDGAR | -0.57% | -2.60% | |
| Form DEFA14A Kyverna Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | -0.57% | -2.60% | |
| Kyverna Therapeutics to Host Conference Call on New Data Across Neuroimmunology Franchise at AAN 2026 | Press release | GlobeNewswire | +0.33% | +4.24% | |
| Form EFFECT Kyverna Therapeutics, | SEC filing · Form EFFECT | SEC EDGAR | +1.13% | +1.13% | |
| Form 10-K Kyverna Therapeutics, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -0.50% | -2.86% | |
| Form 8-K Kyverna Therapeutics, For: Mar 26 | SEC filing · Form 8-K | SEC EDGAR | -0.50% | -2.86% | |
| Form S-3 Kyverna Therapeutics, | SEC filing · Form S-3 | SEC EDGAR | -0.50% | -2.86% | |
| Form S-8 Kyverna Therapeutics, | SEC filing · Form S-8 | SEC EDGAR | -0.50% | -2.86% | |
| Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results | Press release | GlobeNewswire | -0.50% | -2.86% | |
| Kyverna Therapeutics to Present New Data from Neuroimmunology Franchise at AAN 2026 | Press release | GlobeNewswire | -1.15% | -2.99% | |
| Kyverna Therapeutics to Participate in Upcoming March Investor Conferences | Press release | GlobeNewswire | +0.00% | -3.14% | |
| Form 8-K Kyverna Therapeutics, For: Feb 24 | SEC filing · Form 8-K | SEC EDGAR | +1.08% | +0.63% | |
| Kyverna Therapeutics Appoints Biotech Leaders Sravan Emany and Andrew Miller to Board of Directors | Press release | GlobeNewswire | +1.08% | +0.63% | |
| Form 8-K Kyverna Therapeutics, For: Jan 29 | SEC filing · Form 8-K | SEC EDGAR | +1.68% | -0.36% | |
| Kyverna Therapeutics Appoints Mayo Pujols as Chief Technology Officer | Press release | GlobeNewswire | +1.68% | -0.36% | |
| Form 8-K Kyverna Therapeutics, For: Jan 08 | SEC filing · Form 8-K | SEC EDGAR | -3.61% | -0.84% | |
| Kyverna Therapeutics Provides Corporate Update and Outlines 2026 Strategic Priorities at the J.P. Morgan Healthcare Conference | Press release | GlobeNewswire | -3.61% | -0.84% | |
| Kyverna Therapeutics to Present at the J.P. Morgan 2026 Healthcare Conference | Press release | GlobeNewswire | -0.79% | -8.45% | |
| Form 8-K Kyverna Therapeutics, For: Dec 17 | SEC filing · Form 8-K | SEC EDGAR | -1.98% | -1.13% | |
| Kyverna Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock | Press release | GlobeNewswire | +1.30% | +0.00% | |
| Form 8-K Kyverna Therapeutics, For: Dec 15 | SEC filing · Form 8-K | SEC EDGAR | -2.54% | -11.31% | |
| Kyverna Therapeutics Announces Positive Topline Data from Registrational KYSA-8 Trial of Miv-cel (KYV-101) in Stiff Person Syndrome | Press release | GlobeNewswire | -2.54% | -11.31% | |
| Kyverna Therapeutics Announces Proposed Public Offering of Common Stock | Press release | GlobeNewswire | +3.61% | -2.75% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the KYTX section they belong to.
Where else KYTX is measured.
KYTX earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Kyverna Therapeutics, Inc.'s median reaction calculated?
Every labeled KYTX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 1,026 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 40% of KYTX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does KYTX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.